Micron's HBM cycle: can AI memory change the boom-bust math?
A Micron five-year double thesis focused on HBM demand, DRAM/NAND cycle discipline, capital intensity, and whether AI memory improves through-cycle economics.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
24Results19Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
Micron: AI memory scarcity is rewriting the cycle
A refreshed Micron Technology thesis using latest official May 2026 data, Q2 FY2026 results, HBM4 production, AI server memory demand, data-center mix, U.S. manufacturing updates, capex, balance-sheet strength, and cycle risk.
OpenTSMC's AI foundry test: growth, capex, and geopolitical risk
A TSMC five-year double thesis focused on advanced-node foundry leadership, advanced packaging, AI customer demand, capex, margins, and Taiwan risk.
OpenTSMC: the AI foundry moat with a geopolitical discount
A Coverage Bootstrap TSMC company evaluation covering advanced-node foundry leadership, CoWoS, customers, margins, capex, global fabs, Taiwan risk, and valuation setup.
OpenNVIDIA's next five years: can AI earnings outrun valuation risk?
A filing-led NVDA five-year double thesis focused on data-center demand, CUDA lock-in, networking attach, margin durability, and valuation risk.
OpenNVIDIA: the AI factory tollbooth, priced for proof
A Coverage Bootstrap NVIDIA company evaluation covering AI accelerators, CUDA, networking, data-center concentration, margins, export controls, valuation risk, and proof gates.
OpenGTLB: GitLab is growing into DevSecOps scale, but profitability is still the gate
GitLab reported FY2026 revenue of $955.2 million, gross profit of $834.5 million, operating loss of $70.5 million and operating cash flow of $232.9 million. The setup depends on DevSecOps adoption, platform consolidation, gross-margin durability, operating dis
OpenBroadcom's AI cash-flow test: custom chips, Ethernet, and VMware
A Broadcom five-year double thesis focused on custom AI silicon, Ethernet networking, VMware free cash flow, customer concentration, and integration risk.
OpenBroadcom: custom AI silicon plus VMware cash flow
A Coverage Bootstrap Broadcom company evaluation covering custom AI silicon, Ethernet networking, VMware, free cash flow, customer concentration, integration risk, and valuation discipline.
OpenASML's bottleneck advantage: can EUV scarcity still compound?
An ASML five-year double thesis focused on EUV scarcity, High-NA adoption, China/export-control risk, bookings visibility, and semiconductor capex cycles.
OpenASML Holding: the company behind the chip industry's narrowest bottleneck
A Coverage Bootstrap ASML company evaluation covering the business model, EUV and DUV products, customers, moat, financial quality, export-control risk, valuation setup, and watchlist triggers.
OpenAIIA: the AI shell has cash, a clock, and no target yet
AI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
OpenAFJK: 1.04 million public shares left to carry a $1.5 billion hydrogen deal
Aimei Health is no longer a healthcare-search story. It is a high-risk de-SPAC watch where a small remaining SPAC trust is trying to close a $1.5 billion all-share United Hydrogen transaction.
OpenAEXA: $351M in trust, no operating business, and a deadline that matters
AEXA is not a business yet. It is a NYSE-listed SPAC with $351.4 million in trust, $0.3 million of cash outside trust, no selected target as of March 31, 2026, and public shareholder economics that turn on redemption value, sponsor incentives and the future de
OpenAeva: the LiDAR design-win story racing a $35M quarterly loss
Aeva has the kind of customer list lidar startups chase: Daimler Truck, a Top 10 European OEM, NVIDIA, Forterra, Nikon and smart-infrastructure deployments. The catch is that revenue is still $6.3 million a quarter, broad-based deliveries are not expected in 2
OpenActivate Energy: The $230 Million Oil-and-Gas SPAC Still Hunting for a Deal
Activate Energy has no wells, no operating revenue, and no target yet. The source-backed story is a $230.6 million trust account, a December 2027 deal clock, oil-and-gas sponsor ambition, and a structure where Class A shares and warrants carry very different r
OpenAnalog Devices: the analog chip giant riding AI racks while factories thaw
ADI is not a pure AI stock. It is a cash-rich analog semiconductor leader where industrial recovery, automotive resilience, and data-center infrastructure orders are now arriving at the same time.
OpenADAC: the $230 million blank check that still has to find a real company
American Drive Acquisition Company gives investors a documented SPAC trust, a defense/logistics/technology/AI search mandate, and no operating target yet. The useful question is whether the eventual deal beats the promote, warrants, redemption risk, and deadli
OpenAverin Capital (ACAA): the $284 million health-tech blank check with no company yet
ACAA gives investors a real trust account, a health-and-technology sponsor story, and almost no operating company to analyze. The question is whether that blank check becomes a disciplined de-SPAC or another dilution machine.
OpenAxcelis: the implant specialist waiting for memory to rescue a power-chip hangover
Axcelis has a focused ion-implant franchise, a sizable installed-base service layer, strong cash and investment liquidity, and Veeco optionality. The hard part is that power and mature-node digestion have pulled revenue down, backlog is lower, export controls
Open